Last updated: August 17, 2026
Cotellic, Roche’s cobimetinib, is a mature targeted oncology product with declining commercial value. Its market is limited by combination-only use with Zelboraf, competition from newer BRAF/MEK regimens, declining melanoma incidence in advanced treatment cohorts, and the absence of a broad standalone indication. Roche’s reported Cotellic sales have fallen from roughly CHF 200 million-plus annually to approximately CHF 150 million, while key U.S. patent protection extends into the early 2030s based on listed compound and formulation rights. The product remains commercially relevant in selected BRAF V600-mutant melanoma patients but has a limited growth path.
What is Cotellic and how is it used?
Cotellic is cobimetinib fumarate, an oral MEK1/2 inhibitor marketed by Genentech, Roche’s U.S. operating company. The drug is approved in combination with vemurafenib, marketed as Zelboraf, for adults with unresectable or metastatic melanoma whose tumors carry a BRAF V600E or V600K mutation [1].
The approved regimen is:
| Product |
Dose |
Administration |
| Cotellic |
60 mg once daily |
Days 1 through 21 of each 28-day cycle |
| Zelboraf |
960 mg twice daily |
Continuous administration |
Cotellic received U.S. Food and Drug Administration approval on November 10, 2015, following approval of Zelboraf as a BRAF inhibitor [1]. The product is also approved in the European Union and other international markets for BRAF-mutated advanced melanoma [2].
Cobimetinib blocks MEK signaling downstream of mutant BRAF. The combination strategy was designed to delay or reduce resistance associated with BRAF inhibitor monotherapy.
What is the current market position of Cotellic?
Cotellic occupies a narrow position in the melanoma market. Its principal commercial constraints are clinical and competitive rather than manufacturing-related.
Cotellic’s principal market constraints
- The approved use requires combination with Zelboraf.
- BRAF/MEK combination products have become the treatment standard for BRAF-mutant advanced melanoma.
- Competing combinations include Tafinlar plus Mekinist and Braftovi plus Mektovi.
- Immunotherapy combinations are used extensively in first-line advanced melanoma, reducing the addressable population for targeted therapy.
- Cotellic has not established a broad commercial franchise outside melanoma.
The main competitors are:
| Product |
Active ingredients |
Company |
Strategic position |
| Cotellic plus Zelboraf |
Cobimetinib plus vemurafenib |
Roche |
Original BRAF/MEK combination; mature product |
| Tafinlar plus Mekinist |
Dabrafenib plus trametinib |
Novartis |
Broadly established BRAF/MEK competitor |
| Braftovi plus Mektovi |
Encorafenib plus binimetinib |
Pfizer, formerly Array/Bristol Myers Squibb commercial rights |
Important competitor with differentiated dosing and efficacy profile |
| Zelboraf monotherapy |
Vemurafenib |
Roche |
Older BRAF inhibitor, generally less competitive as monotherapy |
Clinical practice has increasingly favored combinations with stronger durability, more convenient dosing, or greater physician familiarity. Cotellic’s commercial performance is therefore tied to the residual use of the Roche BRAF/MEK regimen rather than to expansion of the MEK inhibitor class.
What is Cotellic’s financial trajectory?
Roche does not publicly disclose Cotellic operating profit, gross margin, prescription volume, or regional profitability. Public reporting provides product sales, generally in Swiss francs.
Reported and estimated Roche sales trend
| Fiscal year |
Approximate Cotellic sales |
Direction |
| 2020 |
CHF 220 million |
Mature |
| 2021 |
CHF 205 million |
Declining |
| 2022 |
CHF 180 million |
Declining |
| 2023 |
CHF 160 million to CHF 180 million |
Declining |
| 2024 |
Approximately CHF 140 million to CHF 160 million |
Declining |
The reported trend indicates a low-single-digit to mid-teens annual decline depending on the period measured. Exchange-rate movements affect the Swiss-franc presentation, but the underlying drivers are loss of share to competing BRAF/MEK combinations, treatment sequencing changes, and market maturity [3, 4].
Cotellic is not a major contributor to Roche’s group revenue. Roche generated more than CHF 58 billion in pharmaceutical sales in 2023, placing Cotellic at well below 1% of group pharmaceutical revenue [3].
Revenue exposure
Cotellic’s financial exposure is concentrated in:
- Advanced BRAF V600-mutant melanoma.
- Markets where Roche retains reimbursement for the Zelboraf combination.
- Patients who receive targeted therapy rather than immunotherapy first.
- Regions without aggressive substitution by competing BRAF/MEK regimens.
The product’s cost base is likely favorable because it is an established oral small molecule with mature manufacturing and distribution infrastructure. However, declining volume reduces operating leverage and weakens the commercial justification for additional clinical development.
When does Cotellic lose exclusivity?
Cotellic does not have one single exclusivity date. Its protection is divided among regulatory exclusivity, compound patents, formulation patents, and method-of-use patents.
U.S. regulatory exclusivity
Cotellic was approved in 2015 under a new drug application. Any original five-year new chemical entity exclusivity has expired. The product therefore depends primarily on patent protection and commercial differentiation rather than remaining FDA regulatory exclusivity.
The drug may retain pediatric exclusivity only if the FDA granted and recorded a qualifying six-month extension. Public commercial analyses should distinguish pediatric exclusivity from the core patent term because the former does not create an independent long-term barrier to generic entry.
U.S. patent protection
The Cotellic patent estate includes rights directed to:
- Cobimetinib and related chemical compounds.
- Pharmaceutical compositions.
- Oral dosage forms.
- Methods of treating BRAF-mutant cancers.
- Combination treatment with vemurafenib.
Public patent databases and FDA Orange Book records indicate that key U.S. protection for cobimetinib extends into the early 2030s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the scope of any listed patent [5, 6].
The practical generic-entry date may be earlier than the latest listed expiration if an ANDA applicant files a valid Paragraph IV certification and prevails in litigation, or if Roche settles on an agreed entry date.
What patents protect Cotellic?
The most commercially relevant patent categories are listed below.
| Patent category |
Protected subject matter |
Commercial role |
| Composition of matter |
Cobimetinib and related chemical structures |
Primary barrier to generic substitution |
| Salt and solid-state forms |
Cobimetinib fumarate and pharmaceutical forms |
Can complicate API and finished-dose replication |
| Formulation |
Oral tablets and compositions |
Supports Orange Book listing where applicable |
| Method of use |
Treatment of BRAF V600-mutant melanoma |
Limits labeled generic use and skinny-label strategy |
| Combination therapy |
Cobimetinib with vemurafenib |
Protects the approved therapeutic regimen |
The compound patent is normally the most valuable asset because it can block a generic version of the active ingredient across indications. Formulation and method-of-use patents are narrower. Their value depends on whether the generic seeks a full label, a carve-out, or an alternative formulation.
How strong is the Cotellic patent estate?
The estate is commercially meaningful but not exceptionally broad.
Its strengths are:
- A small-molecule compound right with protection extending beyond the product’s original regulatory exclusivity.
- A well-defined approved use in a genetically selected cancer population.
- Combination-treatment patents that may complicate labeling and clinical positioning.
- Roche control of both Cotellic and Zelboraf, which supports coordinated lifecycle management.
Its weaknesses are:
- A narrow approved indication.
- Heavy dependence on an older companion BRAF inhibitor.
- Limited apparent expansion into additional high-value indications.
- Potential for generic applicants to challenge composition, formulation, or validity claims.
- Reduced economic value as physicians shift to rival BRAF/MEK combinations.
What is the Orange Book status of Cotellic?
Cotellic is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under cobimetinib fumarate and NDA 206192 [5].
The Orange Book is relevant because it identifies patents that the reference drug sponsor asserts cover the drug or an approved method of use. An ANDA applicant must address listed patents through one of four certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will wait until patent expiration.
- Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed.
The Orange Book listing does not guarantee that every listed patent will block approval through its full term. It creates a framework for patent certification and potential litigation.
Which companies are challenging Cotellic?
No major publicly disclosed Paragraph IV litigation involving a Cotellic generic has become a defining commercial event in the public record reviewed through June 2024. That does not eliminate future challenge risk. Mature oncology products with declining sales can attract generic filings when the remaining market is large enough to support litigation.
Potential challengers would likely include:
- Large generic manufacturers with oncology portfolios.
- Specialty generic companies focused on high-value oral anticancer products.
- Contract development and manufacturing organizations partnering with ANDA sponsors.
A Paragraph IV filing could trigger a 30-month FDA approval stay if Roche brought an infringement action within the statutory period. The commercial outcome would depend on the challenged patent, the availability of a skinny label, and the settlement terms.
What generic entry risks exist for Cotellic?
The highest-probability scenario is a delayed, potentially negotiated generic entry rather than an immediate market break.
Generic launch scenarios
| Scenario |
Likely commercial effect |
| No challenge until late patent term |
Roche retains declining residual revenue until patent expiry |
| Paragraph IV challenge defeated |
Entry remains blocked; litigation costs increase |
| Paragraph IV settlement |
Generic launch occurs before listed expiration on an agreed date |
| Successful invalidity or noninfringement challenge |
Earlier launch and rapid price erosion |
| Skinny-label launch |
Generic captures prescriptions outside patented methods but may face limited uptake |
| Multiple generic entrants |
Rapid price compression and loss of Roche share |
Because Cotellic is an oral oncology product, generic entry could produce substantial net-price erosion. The erosion may be moderated by restricted use in BRAF-mutant melanoma, specialty pharmacy controls, and the fact that prescribers can switch to alternative BRAF/MEK combinations rather than remain with a generic cobimetinib regimen.
What formulation and manufacturing barriers protect Cotellic?
Cotellic is a conventional oral tablet, not a biologic or complex injectable. Its manufacturing barriers are therefore moderate.
The principal technical requirements are:
- Reproducible synthesis of cobimetinib.
- Control of the fumarate salt and solid-state properties.
- Tablet content uniformity at the 20 mg strength.
- Stability through the approved shelf life.
- Bioequivalence under FDA requirements.
- Compliance with oncology-product manufacturing standards.
The product does not appear to require a delivery platform, device, depot formulation, or specialized biologic manufacturing process. Manufacturing IP can delay development, but it is less likely to prevent a capable generic manufacturer from entering after core composition patents expire or are defeated.
What FDA regulatory risks affect Cotellic?
The FDA label contains significant safety-management requirements. Important risks include:
- Cardiomyopathy and reduced left ventricular ejection fraction.
- Severe dermatologic reactions.
- Hemorrhage.
- Rhabdomyolysis.
- Liver toxicity.
- Photosensitivity.
- Embryo-fetal toxicity.
- Drug interactions involving CYP3A.
The safety profile can affect market share because physicians may favor competing combinations with different monitoring requirements or perceived tolerability advantages. Roche’s label requires monitoring of cardiac function, liver tests, and selected laboratory parameters [1].
The FDA has not converted Cotellic into a broad tumor-agnostic product. A broader approval would be necessary to create a substantial new revenue opportunity, but the available public development record has not produced a major expansion comparable with the original melanoma indication.
What licensing deals affect Cotellic?
Cotellic originated from Exelixis’ MEK program. Roche obtained rights through a global collaboration and licensing arrangement with Exelixis covering cobimetinib development and commercialization [7].
The deal structure matters because Cotellic revenue is not equivalent to Roche net revenue. Roche may owe royalties or other contractual payments under the collaboration. Exelixis has historically reported collaboration revenue associated with cobimetinib, while Roche reports product sales within its pharmaceutical portfolio.
The commercial significance of the collaboration has declined with Cotellic sales. The agreement remains relevant for royalty economics, territory rights, and post-approval obligations, but it does not materially change the product’s competitive position.
What patent litigation and settlements affect Cotellic?
Cotellic’s principal litigation risk is prospective ANDA litigation rather than a major public dispute over marketed use. Key events to monitor include:
- FDA Orange Book additions or deletions.
- Paragraph IV notices to Roche.
- District court complaints within 45 days of notice.
- Patent-term adjustment changes.
- Patent-listing disputes.
- Settlements that establish an authorized or non-authorized generic entry date.
- FDA approval of a cobimetinib ANDA.
A settlement could preserve Roche’s remaining revenue while giving a challenger a controlled launch date. The value of such a settlement would decline as Cotellic sales approach the level at which generic competition produces limited absolute revenue loss.
How does Cotellic compare with competing BRAF/MEK combinations?
| Factor |
Cotellic plus Zelboraf |
Tafinlar plus Mekinist |
Braftovi plus Mektovi |
| BRAF inhibitor |
Vemurafenib |
Dabrafenib |
Encorafenib |
| MEK inhibitor |
Cobimetinib |
Trametinib |
Binimetinib |
| Commercial maturity |
Mature and declining |
Established |
Established competitor |
| Roche control of both agents |
Yes |
No |
No |
| Main market issue |
Dependence on Zelboraf |
Strong physician familiarity |
Competitive efficacy and dosing profile |
| Growth outlook |
Limited |
More resilient |
More resilient than Cotellic |
| Generic risk |
Medium to high over time |
Estate-specific |
Estate-specific |
Cotellic’s biggest disadvantage is strategic dependence on Zelboraf. A competitor with a stronger BRAF inhibitor, broader clinical adoption, or more favorable treatment sequencing can displace the entire combination rather than only the MEK component.
What is the outlook for Cotellic revenue?
Cotellic revenue is likely to continue declining through the remainder of the decade unless Roche obtains a meaningful new indication or reverses competitive share loss. The product can remain profitable because development costs are largely sunk and manufacturing is comparatively straightforward. Its absolute contribution to Roche earnings, however, is small.
The principal value scenarios are:
- Base case: continued annual decline as competing combinations take share.
- Downside case: earlier generic entry combined with further erosion of Zelboraf use.
- Upside case: limited stabilization from label expansion, improved sequencing data, or pricing resilience in selected markets.
- Strategic case: Roche retains the product as part of an integrated melanoma portfolio but allocates little incremental R&D capital.
Key Takeaways
- Cotellic is Roche’s cobimetinib-based MEK inhibitor for BRAF V600-mutant advanced melanoma.
- Its approved use is combination therapy with Zelboraf, creating dependence on an older companion product.
- Roche sales have declined from more than CHF 200 million annually to approximately CHF 150 million.
- Competing combinations from Novartis and Pfizer have constrained market share.
- Core U.S. patent protection extends into the early 2030s based on public Orange Book and patent records.
- Regulatory exclusivity from the 2015 approval has expired; future protection depends primarily on patents.
- No major publicly disclosed Paragraph IV litigation had materially disrupted the product through June 2024.
- Generic entry would likely produce rapid price erosion because Cotellic is an oral small molecule with moderate manufacturing complexity.
- The product remains commercially profitable but has limited growth potential and low exposure to Roche’s consolidated revenue.
FAQs
Is Cotellic still commercially important to Roche?
Cotellic is commercially relevant as a mature oncology product but contributes well below 1% of Roche pharmaceutical sales. Its declining revenue makes it a minor product within Roche’s portfolio.
Does Cotellic have biosimilar risk?
No. Cotellic is a chemically synthesized small molecule, so it faces generic-drug risk rather than biosimilar risk.
Can a generic sell cobimetinib without Zelboraf?
A generic sponsor may seek approval for the same combination label or use a skinny-label strategy if method-of-use patents permit a carve-out. Commercial uptake would depend on the approved label, patent scope, payer policies, and physician willingness to use generic cobimetinib with Zelboraf.
What is the main competitor to Cotellic?
Tafinlar plus Mekinist is one of the strongest competitive alternatives. Braftovi plus Mektovi is also an important BRAF/MEK combination, particularly where physicians prioritize its clinical and dosing profile.
Is Roche developing a next-generation Cotellic product?
The public commercial record does not indicate a major next-generation Cotellic franchise capable of materially changing the product’s revenue trajectory. Cotellic remains primarily a mature melanoma asset.
References
- U.S. Food and Drug Administration. (2015). Cotellic (cobimetinib) prescribing information. https://www.accessdata.fda.gov
- European Medicines Agency. (2015). Cotellic: EPAR product information. https://www.ema.europa.eu
- Roche Holding AG. (2024). Annual report 2023. https://www.roche.com/investors/reports
- Roche Holding AG. (2025). Annual report 2024. https://www.roche.com/investors/reports
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- United States Patent and Trademark Office. (2024). Patent Center and patent term information. https://patentcenter.uspto.gov
- Exelixis, Inc. (2015). Annual report and collaboration disclosures for cobimetinib. https://ir.exelixis.com